EVLO - Evelo Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Evelo Biosciences, Inc.

620 Memorial Drive
Suite 200 West
Cambridge, MA 02139
United States

Full Time Employees75

Key Executives

NameTitlePayExercisedYear Born
Dr. Noubar B. Afeyan Ph.D.Co-founder & ChairmanN/AN/A1963
Dr. Balkrishan GillPres, CEO & DirectorN/AN/A1965
Mr. Jonathan PooleCFO & Treasurer334.79kN/A1975
Dr. Duncan McHale M.D., Ph.D.Chief Medical OfficerN/AN/A1967
Dr. Mark BodmerChief Scientific Officer and Pres of R&DN/AN/A1958
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Evelo Biosciences, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.